These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 7927137

  • 1. Mechanism of transfusion-associated graft-versus-host disease.
    Yasuda H, Ohto H, Abe R.
    Fukushima J Med Sci; 1993 Dec; 39(2):69-75. PubMed ID: 7927137
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of transfusion-associated graft-vs.-host disease: the importance of short tandem repeat analysis.
    Sage D, Stanworth S, Turner D, Navarrete C.
    Transfus Med; 2005 Dec; 15(6):481-5. PubMed ID: 16359419
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention of transfusion-associated graft-vs-host disease.
    Holland PV.
    Arch Pathol Lab Med; 1989 Mar; 113(3):285-91. PubMed ID: 2645855
    [Abstract] [Full Text] [Related]

  • 5. Transfusion associated graft versus host disease.
    Anwar M, Bhatti FA.
    J Ayub Med Coll Abbottabad; 2003 Mar; 15(3):56-8. PubMed ID: 14727344
    [Abstract] [Full Text] [Related]

  • 6. Transfusion-associated graft-versus-host disease.
    Rühl H, Bein G, Sachs UJ.
    Transfus Med Rev; 2009 Jan; 23(1):62-71. PubMed ID: 19056035
    [Abstract] [Full Text] [Related]

  • 7. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature.
    Agbaht K, Altintas ND, Topeli A, Gokoz O, Ozcebe O.
    Transfusion; 2007 Aug; 47(8):1405-11. PubMed ID: 17655584
    [Abstract] [Full Text] [Related]

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 9. Transfusion-associated-graft-vs-host disease in a presumed immunocompetent patient.
    Arsura EL, Bertelle A, Minkowitz S, Cunningham JN, Grob D.
    Arch Intern Med; 1988 Sep; 148(9):1941-4. PubMed ID: 3261972
    [Abstract] [Full Text] [Related]

  • 10. Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood.
    Gilstad C, Roschewski M, Wells J, Delmas A, Lackey J, Uribe P, Popa C, Jardeleza T, Roop S.
    Transfusion; 2012 May; 52(5):930-5. PubMed ID: 21981662
    [Abstract] [Full Text] [Related]

  • 11. Transfusion-associated graft-versus-host disease: an overview and two case reports.
    Spector D.
    Oncol Nurs Forum; 1995 May; 22(1):97-101. PubMed ID: 7708528
    [Abstract] [Full Text] [Related]

  • 12. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion.
    Higgins MJ, Blackall DP.
    Curr Hematol Rep; 2005 Nov; 4(6):470-6. PubMed ID: 16232385
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transfusion-associated graft-versus-host disease in a liver transplant recipient: an unusual presentation and review of the literature.
    O'Brien KL, Pereira SE, Wagner J, Shadman M, Hendrie P, Nelson K, Gernsheimer TB, Price T, Reyes JD, Nester T.
    Transfusion; 2013 Jan; 53(1):174-80. PubMed ID: 22563807
    [Abstract] [Full Text] [Related]

  • 15. Transfusion-associated graft-versus-host disease.
    Rappeport JM.
    Yale J Biol Med; 1990 Jan; 63(5):445-54. PubMed ID: 2293503
    [Abstract] [Full Text] [Related]

  • 16. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease.
    Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, Lucas G, Beatty C, Casbard A, Cohen H.
    Transfusion; 2007 Aug; 47(8):1455-67. PubMed ID: 17655590
    [Abstract] [Full Text] [Related]

  • 17. Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way HLA matching.
    Kamei H, Oike F, Fujimoto Y, Yamamoto H, Tanaka K, Kiuchi T.
    Liver Transpl; 2006 Jan; 12(1):140-5. PubMed ID: 16382466
    [Abstract] [Full Text] [Related]

  • 18. [Graft versus host disease with fatal outcome after administration of filtered erythrocyte concentrates].
    Heim MU, Munker R, Sauer H, Wolf-Hornung B, Knabe H, Holler E, Böck M, Mempel W.
    Beitr Infusionsther; 1992 Jan; 30():178-81. PubMed ID: 1284701
    [Abstract] [Full Text] [Related]

  • 19. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT).
    Bishara A, Amar A, Brautbar C, Condiotti R, Lazarovitz V, Nagler A.
    Exp Hematol; 1995 Dec; 23(14):1667-75. PubMed ID: 8542963
    [Abstract] [Full Text] [Related]

  • 20. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease.
    Shivdasani RA, Anderson KC.
    Leuk Lymphoma; 1994 Oct; 15(3-4):227-34. PubMed ID: 7866271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.